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ABSTRACT 
 
During endochondral bone development, bone-forming osteoblasts have to colonize the 
regions of cartilage that will be replaced by bone. In adulthood, bone remodeling and repair 
require osteogenic cells to reach the sites that need to be rebuilt, as a prerequisite for skeletal 
health. A failure of osteoblasts to reach the sites in need of bone formation may contribute to 
impaired fracture repair. Conversely, stimulation of osteoblast recruitment may be a 
promising osteo-anabolic strategy to improve bone formation in low bone mass disorders 
such as osteoporosis and in bone regeneration applications. Yet, still relatively little is known 
about the cellular and molecular mechanisms controlling osteogenic cell recruitment to sites 
of bone formation. In vitro, several secreted growth factors induce osteogenic cell migration. 
Recent studies started to shed light on the role of such chemotactic signals in osteoblast 
recruitment during bone remodeling. Trafficking of osteoblast lineage cells into new bone 
centers during endochondral bone development and repair is largely confined to 
undifferentiated osteoprogenitors, and coupled to angiogenic invasion of the cartilage 
intermediate. It is well known that blood vessels are absolutely required for bone formation 
and that a close spatial-temporal relationship exists between osteogenesis and angiogenesis. 
Studies using genetically modified mice have identified some molecular constituents of this 
osteogenic-angiogenic coupling. This article reviews the current knowledge on osteoblast 
recruitment to sites of active bone formation in skeletal development, remodeling, and repair, 
considering the role of chemo-attractants for osteogenic cells and the interplay between 
osteogenesis and angiogenesis in the control of bone formation. 
 
  
INTRODUCTION 
 
One of the major goals in the bone field today is to identify new approaches to stimulate bone 
formation. Clinically, anabolic drugs are much needed to help restore the bone mass in 
osteoporotic patients and to improve repair of large bone defects.  
 
Osteoporosis, the disease of ‘porous bones’, is very widespread in older people and imposes a 
huge public health problem. Normal bone is remodeled throughout adult life, undergoing 
continual renewal and adaptation to physical exercise, diet and other factors. This is mediated 
by the balanced activities of bone-forming osteoblasts and bone-resorbing osteoclasts. 
Osteoporosis results from a dysregulation of this finely concerted balance, with osteoclastic 
bone resorption exceeding osteoblastic bone formation, leading to net bone loss. Current 
therapies effectively halt bone destruction, but are unable to reverse the disease; there is a 
large need for additional anabolic drugs that stimulate bone formation and improve bone 
strength beyond what can be achieved with antiresorptives (Baron and Hesse, 2012, Rachner 
et al., 2011). 
Key to the development of new anabolic bone therapies is a full understanding of the 
molecular mechanisms that accommodate the functioning of bone-producing osteoblasts. 
Osteoblast differentiation, from mesenchymal precursors that first commit to the lineage as 
osteoprogenitors, is therefore intensively studied. One aspect of bone formation that received 
relatively less attention is the recruitment of osteogenic cells to the active bone surfaces. Yet, 
mature osteoblasts are located onto the bone surfaces, whereas osteoprogenitors reside at the 
periphery of the bone shaft or dispersed in the bone environment. The recruitment of 
osteoprogenitors to the bone surface is therefore an indispensable aspect of bone formation; 
and, modulating this process could offer unique opportunities for anabolic treatment of 
osteoporosis and other metabolic bone disorders. Likewise, increased attraction of osteoblasts 
to sites in need of bone formation could be a promising strategy to treat compromised fracture 
repair and improve (tissue-engineered) bone regeneration. Fracture repair in the adult closely 
resembles bone development and recapitulates several of the main molecular pathways 
operating in fetal life (Gerstenfeld et al., 2003, Schindeler et al., 2008). A thorough 
understanding of the mechanisms governing embryonic development and normal physiology 
will thus add valuable insights in disease and regeneration, and be the basis for new 
therapeutic developments in the future.  
 
Despite the great variety of shapes and sizes, bones develop and grow through a small number 
of cellular mechanisms. Endochondral bone formation is the most common strategy, forming 
all the long bones of the axial (vertebrae, ribs) and appendicular skeleton (limbs). This term 
indicates that mineralized bones form by organizing the cells and matrix of bone on 
scaffolding cartilage models. Two absolute requirements for normal endochondral bone 
formation are, firstly, the provision of bone-forming osteoblasts and secondly, progressive 
neovascularization of the growing bone. These two aspects go hand in hand, during 
development as well as in healing bone fractures. In fact, bone formation in virtually all 
settings occurs in close spatial and temporal association with vascularization of the ossified 
tissue, a concept termed angiogenic-osteogenic coupling (Schipani et al., 2009, Maes, 2013, 
Riddle et al., 2009). The interplay is dynamic and reciprocal, in that the cells of bone on the 
one hand depend on the signals, oxygen, and nutrient delivery via the blood stream, while on 
the other hand they influence the vascular arrangement and function. Moreover, some 
osteogenic cells with the capacity to become functional osteoblasts reside in the blood vessel 
wall. Altogether, the current knowledge suggests that osteoprogenitors and endothelial cells 
may be attracted to sites where vascularized bone is to be formed by common chemotactic 
stimuli and/or osteo-angiogenic coupling factors. The insights gained over the years through 
in vitro studies and a myriad of genetically modified animal models on these regulatory cues 
is reviewed here.  
 
 
OSTEOBLAST ORIGIN AND RECRUITMENT INTO DEVELOPING LONG BONES  
 
Ossification in skeletal development 
 
The vertebrate skeleton is composed of over 200 individual bones, each with its own unique 
shape, size, location and function. The two major categories of bones are the flat bones, of 
which the skull is the most typical representative, and the long bones that comprise most 
bones in the skeleton, including those of the limbs (Figure 1). The flat bones consist of 
compact bone with a layer of interspersed bone marrow. The long bones characteristically 
consist of a shaft or diaphysis in the middle made up by dense cortical or compact bone, 
surrounding the medullary cavity, and epiphyses at both ends; the region in between is termed 
the metaphysis. The ends of the bone contain a honeycomb-like trabecular network of spongy 
bone on the inside. The cartilaginous growth plates, responsible for growth, are located 
between the epiphysis and diaphysis, until they disappear (‘close’) at puberty in humans. The 
outer surface of the bone shaft is covered by a fibrous connective tissue termed periosteum, 
which is important for growth and fracture repair; the inner lining of the cortical bone of the 
diaphysis is termed the endosteum. At the epiphyses a layer of articular cartilage covers the 
bone, which is important for the functioning of the joints. 
 
The flat bones of the skull and the long bones of the axial skeleton and the limbs develop 
through different mechanisms: intramembranous and endochondral ossification, respectively 
(Figure 1). Skeletal morphogenesis involves highly coordinated sequential steps of cell 
migration, aggregation, condensation, and organogenesis. Cells that originate from the cranial 
neural crest, the somites and the lateral plate mesoderm form the skeletal structures. Before 
intramembranous ossification can start, neural crest and paraxial mesodermal cells need to 
migrate in the right time frame to the right place for proper formation of the sutures (Helms 
and Schneider, 2003). This is followed by the condensation of mesenchymal cells that will 
form the skeletal structures, and their subsequent differentiation into osteoblasts. The 
osteoblasts deposit bone matrix rich in type I collagen (Col1) that next becomes mineralized. 
Endochondral ossification comprises of a more complicated process that gives rise to the long 
bones of the axial skeleton, derived from the paraxial mesoderm, and the appendicular 
skeleton, derived from lateral plate mesoderm (Shum et al., 2003). At sites where the bones 
will be formed, mesenchymal progenitor cells aggregate and form high-density 
condensations, representing the molds of the future skeletal elements. In mice, this process 
takes place around E10-E12. These condensed mesenchymal cells differentiate into 
chondrocytes, forming a scaffolding anlage of cartilage that is gradually replaced by bone 
during endochondral ossification. The mechanisms underlying the early migration, 
condensation, segmentation and differentiation events, define the precise arrangement of the 
individual anatomic elements and their patterning along the proximal-distal, dorsal-ventral, 
and anterior-posterior body axes. Excellent reviews are available on this subject (Tabin and 
Wolpert, 2007, Towers et al., 2012); here, we will focus on the later process of actual bone 
formation or ossification. 
 
Ossification in developing long bones starts in the perichondrium, the connective tissue 
surrounding the cartilaginous template, where cells differentiate into osteoblasts that start to 
deposit and mineralize a structure called the ‘bone collar’ around the cartilage mold. This 
bone collar forms the initiation site of the cortical bone, the dense outer envelope of compact 
bone that provides most of the strength and rigidity to the long bones. The actual process of 
‘endochondral’ ossification is triggered shortly thereafter, around E14-E15 in mice, when the 
hypertrophic chondrocytes in the center of the cartilage mold become invaded by blood 
vessels along with osteoclasts and osteoprogenitors from the surrounding perichondrium (see 
further). As a result, the cartilage template is progressively eroded and replaced by trabecular 
bone and bone marrow, a region initially termed the primary ossification center. In the 
metaphysis, hypertrophic cartilage of the growth cartilage is continually replaced with 
trabecular bone, a process that relies heavily on angiogenesis and mediates longitudinal bone 
growth. After birth, the cartilage of the epiphysis also becomes invaded by blood vessels, 
emanating from the vascular network around the tissue. This gives rise to the secondary 
ossification center. The remaining cartilage between the ossification centers now forms a true 
growth plate ‘plate’, driving further longitudinal bone growth. In humans, the deposition of 
cartilage ceases at puberty; the metaphysis fuses with the epiphysis and growth stops. In mice, 
longitudinal growth slows dramatically at puberty, but the growth plates do not completely 
disappear. 
Hence, in endochondral bones, osteoblast lineage cells will populate the region formerly 
occupied by chondrocytes, where they will differentiate and deposit osteoid on cartilage 
remnants. Understanding the process of their recruitment to the sites where bone will be 
formed may eventually help identify novel therapeutic targets to treat osteoporosis, improve 
impaired bone healing and contribute to the engineering of bone regeneration applications. 
 
 
Osteoblast differentiation 
 
Osteoblast lineage cells, encompassing osteoprogenitors, osteoblasts and osteocytes, derive 
from mesenchymal progenitor cells commonly referred to as mesenchymal stem cells 
(MSCs). MSCs from bone marrow, periosteum, and other sources are capable of 
differentiating along the osteoblastic, chondrogenic, adipogenic, and/or myogenic cell 
lineages (Augello et al., 2010, Tare et al., 2008). These differentiation processes are tightly 
regulated by transcription factors in a spatially and temporally controlled manner (Long, 
2012, Hartmann, 2009) (Figure 2). 
The commitment of mesenchymal progenitor cells into chondrogenic and osteogenic lineages 
starts with the expression of Sox9 (Akiyama et al., 2005). In bones that develop through 
endochondral ossification, a stage of bipotency of osteo-chondroprogenitors is recognized 
before the cells specify in either the chondrocyte or the osteoblast lineage. Early osteoblast 
progenitors express Runx2, a Runt domain containing transcription factor that is absolutely 
required for the differentiation of osteoblasts as well as for the appropriate functioning of 
mature osteoblasts. Runx2 is viewed as the master controller of osteoblastogenesis. Its 
deletion in mice resulted in a cartilaginous skeleton with absence of osteogenic differentiation 
and bone formation (both intramembranous and endochondral) (Komori, 2010). A similar 
phenotype was observed in mice with inactivation of the Sp7 gene encoding Osterix (Osx), a 
second transcription factor expressed in osteoprogenitors that is essential for osteoblast 
differentiation and function (Nakashima et al., 2002). In situ hybridization studies using these 
knockout mouse models revealed that the expression of Runx2 was preserved in the 
perichondrium of endochondral bones as well as in the condensations of membranous skeletal 
elements of Osx null mice, whereas conversely, Osx expression was undetectable in the 
perichondrium surrounding the cartilage anlagen of mice lacking Runx2 (Nakashima et al., 
2002). These findings established that Osx is genetically downstream of Runx2; yet, how 
much Runx2+ and Runx2+Osx+ osteogenic cell populations in vivo may or may not differ 
from each other in their molecular and functional characteristics remains to be clarified. Both 
Runx2 and Osx support the downstream effects of multiple osteogenic factors and regulate 
gene expression of many major bone matrix proteins during osteoblast differentiation. Runx2 
also keeps a pool of osteoblasts in an immature stage and regulates chondrocyte 
differentiation (see below) (Long, 2012, Komori, 2010).  
The third important transcription factor regulating osteoblast differentiation is β-catenin, the 
major mediator of canonical Wnt-signaling. β-catenin is indispensible for mesenchymal 
precursor cells to become Runx2+Osx+ and for the latter to differentiate into mature 
osteoblasts; deletion of the gene encoding β-catenin in Osx+ osteoprogenitors inhibited their 
terminal differentiation to mature osteoblasts, and instead induces the expression of 
chondrocytic or adipocytic markers (Rodda and McMahon, 2006, Song et al., 2012, Chen and 
Long, 2013, Hill et al., 2005, Case and Rubin, 2010). 
 
As they mature, osteoblasts start producing abundant matrix proteins, including large 
quantities of the main bone constituent type I collagen, which they deposit as osteoid or non-
mineralized bone matrix. This osteoid becomes mineralized by accumulation of calcium 
phosphate in the form of hydroxyapatite, a process executed by mature osteoblasts that 
reached a differentiation stage in which they typically express osteocalcin. Some of the cells 
ultimately undergo apoptosis or become bone lining cells, while another subset of osteoblasts 
becomes embedded in the bone matrix and further differentiates to osteocytes (expressing 
dentin matrix protein 1 (Dmp1) and sclerostin). Osteocytes form a canalicular network of 
long protrusions to communicate with other osteocytes, and to osteoclasts and osteoblasts on 
the bone surface. They are highly mechano-sensitive cells and prime regulators of bone 
remodeling (Bonewald, 2011). 
 
The line of progression of osteoblast differentiation is illustrated in Figure 2, with indication 
of some of the abovementioned markers typifying particular stages of the process. The 
promoters of several of these genes have been used to drive Cre expression in mice, 
constitutively and/or in temporal-regulated ways, to target genes of interest in genetically 
modified mice. The Cre-strains used most routinely in studies of osteoblast lineage cells 
include those driven by the Osx promoter, various versions of the Col1 promoter, and the 
osteocalcin and Dmp1 gene promoters (Figure 2) (Elefteriou and Yang, 2011). 
 
 
Origin of osteoblasts in endochondral bone development: the perichondrium as source 
of osteoprogenitors for trabecular bone formation 
 
In bones developing by endochondral ossification, the first committed osteoblast lineage cells 
expressing the early markers Runx2 and Osx appear in the perichondrium surrounding the 
cartilage anlagen; at least a subset of these cells differentiate to mature, bone-forming 
osteoblasts that deposit the bone collar, the prelude of the later cortical bone shaft (Maes et 
al., 2010c). This early osteoblast differentiation program proceeds in tight coordination with 
the hypertrophic differentiation of chondrocytes in the bone model, through an abundant 
molecular cross talk between the perichondrium and the underlying cartilage. On the one 
hand, perichondrial cells produce a myriad of paracrine factors that can influence the 
proliferation and differentiation of the adjacent chondrocytes, including fibroblast growth 
factors (FGFs), bone morphogenetic proteins (BMPs), and Wnts (Kronenberg, 2007). On their 
turn, chondrocytes in the bone anlagen and fetal growth plates produce signals, such as Indian 
hedgehog (Ihh), that direct mesenchymal cells in the surrounding perichondrium towards the 
osteoblast fate by inducing Runx2 expression (Kronenberg, 2003, Kronenberg, 2007). 
Conversely, Runx2 reciprocally also regulates Ihh expression and hypertrophic differentiation 
(Long, 2012). Ihh, a member of the conserved family of hedgehog proteins, is produced by 
the pre-hypertrophic and early hypertrophic chondrocytes of the fetal cartilage, and signals 
through the receptor Patched (Ptc) in adjacent chondrocytic and perichondrial domains. Via a 
negative feedback signaling pathway with parathyroid hormone-related peptide (PTHrP), Ihh 
regulates the pace of hypertrophic differentiation in the growth plate (Kronenberg, 2003). In 
addition, localized signaling by Ihh induces osteoblastogenesis and bone collar formation in 
the perichondrium immediately adjacent to the (pre-)hypertrophic chondrocytes by 
stimulating the expression of Runx2. Through these combined functions, Ihh orchestrates the 
spatiotemporal alignment of hypertrophic chondrocyte maturation with perichondrial 
osteoblast differentiation and bone collar formation (Long, 2012, Kronenberg, 2007, 
Kronenberg, 2003). 
 
Establishment of the bone collar is associated in time and place with vascular accumulation in 
the mid-diaphyseal perichondrial region. The cartilaginous tissue that prefigures the future 
bone itself is intrinsically avascular. As it grows in early development, chondrocytes 
vigorously proliferate and produce abundant extracellular matrix largely consisting of type II 
collagen and proteoglycans. At a certain moment, the chondrocytes exit the cell cycle, 
undergo maturation and finally become hypertrophic; they now typically secrete a matrix rich 
in type X collagen that partially becomes calcified. At this stage they also produce angiogenic 
stimuli, such as VEGF (see further), attracting blood vessels to the inner perichondrial tissue 
layers immediately adjacent to the hypertrophic cartilage (Maes, 2013). These blood vessels 
will subsequently, around E14.5 in most long bones of the mouse, invade the hypertrophic 
portion of the cartilage anlagen. As the cartilage matrix becomes resorbed by osteoclasts, 
osteoblast progenitors populate the region formerly occupied by chondrocytes, differentiate 
into osteoblasts, and deposit osteoid on cartilage remnants. By E16.5, the middle portion of 
the cartilage is replaced by the primary ossification center, the highly vascularized region 
inside the bone shaft occupied by trabecular bone and bone marrow and that will further 
expand as the bone lengthens. The hematopoietic (stem) cells that are to constitute the bone 
marrow travel through the blood stream into the bone environment (Christensen et al., 2004), 
but the origin and entry of the osteogenic stromal cells and osteoblasts giving rise to the 
trabecular bone compartment inside the long bones was long elusive. Of several hypotheses 
raised (see below), the perichondrium represented a prime candidate source to provide these 
cells. In an ex vivo assay using embryonic limb explants grown underneath the renal capsule 
of adult mice, the perichondrium was shown to deliver cells to the inside of the cultured 
bones; moreover, if the perichondrium was removed from the explants, they did not develop a 
primary ossification center and instead remained as entirely cartilaginous rudiments (Colnot 
et al., 2004). Lineage tracing studies recently endorsed perichondrial osteoprogenitors as 
source of osteoblasts for trabecular bone formation in endochondral ossification in vivo 
(Maes et al., 2010c). Specifically, cells in the perichondrium characterized by expression of 
the early osteogenic marker Osx were found to travel to the inside of the developing bone and 
give rise to trabecular osteoblasts, osteocytes and stromal cells populating the primary 
ossification center. The specific tracking of the cells from their site of origin was made 
possible by the generation of 2 transiently tamoxifen-inducible transgenic mouse lines, 
carrying Cre-ERt transgenes driven by the Osx and Col1 (3.2 kb) gene promoters that become 
expressed in osteoprogenitors and mature osteoblasts, respectively. These mice were bred to 
Rosa26R-LacZ reporter mice to allow their genetic labeling with β-galactosidase (LacZ) 
expression upon the administration of tamoxifen. A single bolus injection of tamoxifen at 
E12.5 or E13.5 was successful in marking a number of Cre-ERt-expressing cells in the 
perichondrium surrounding the avascular cartilaginous bone rudiment prior to its initial 
vascular invasion, as visualized by staining for the LacZ substrate X-gal. Pulse-chase studies 
allowed the specific tracing of these cells within the heterogeneous bone context, following 
their fates during bone development. These studies revealed that between embryonic day E14 
and E16, Osx/LacZ+ osteoprogenitors moved from the perichondrium to the inside of the 
shaft to initiate the nascent primary ossification center. Some of these cells and their progeny 
differentiated into mature bone-anchored osteoblasts that became responsible for trabecular 
bone formation, while another portion remained part of the immature osteogenic stroma in the 
intertrabecular bone and marrow space. In contrast, similarly labeled perichondrial mature 
osteoblasts expressing the Col1-CreERt transgene (Col1/LacZ+ cells) mostly stayed in the 
perichondrial area enveloping the bone shaft and generated the outer cortical bone (Maes et 
al., 2010c).  
 
These data indicated that stage-selective subsets of osteoblast lineage cells originating from 
the early fetal perichondrium display differential destinies in developing bones. 
Osteoprogenitors, in addition to becoming bone collar osteoblasts, are also recruited to the 
inside of the bone to form the trabecular region, while osteoblasts that matured while residing 
in the perichondrium predominantly build the cortex (Maes et al., 2010c). These findings do 
not exclude other potential sources of trabecular osteoblasts in endochondral bone 
development. For instance, circulating progenitors delivered through the blood stream, 
chondrocytes, and pericytes, have been and are being considered as cellular sources of the 
osteoblastic cells that produce trabecular bone (Colnot et al., 2004, Galotto et al., 1994, 
Khosla et al., 2010, Roach and Erenpreisa, 1996). To date, however, evidence for and 
estimates of the respective contributions of these potential osteoblast sources relative to the 
perichondrial osteoprogenitors is only sparsely available. Hypertrophic chondrocytes are 
generally thought to undergo apoptosis, but the hypothesis that they may exhibit osteoblastic 
transdifferentiation potential has been proposed decades ago and remains a matter of debate, 
speculation, and research (Gentili et al., 1993, Galotto et al., 1994, Roach and Erenpreisa, 
1996, Shapiro et al., 2005, Hilton et al., 2007). Pericytes have been amply proposed as 
osteoprogenitors and found capable of differentiating into functional osteoblasts (Crisan et al., 
2008, Khosla et al., 2010, Sacchetti et al., 2007, Kalajzic et al., 2008). Several primitive 
mesenchymal cell populations residing in perivascular locations have been recognized in 
bone, including CXCL12-abundant reticular (CAR) cells, Nestin-expressing cells, and cells 
marked by expression of Osx (in the mouse) and of the cell surface marker CD146 (in adult 
human bone) or (Mendez-Ferrer et al., 2010, Sugiyama et al., 2006, Sacchetti et al., 2007, 
Maes et al., 2010c). Such cells may possibly constitute reserve precursors that can be 
activated later to complete an inherent osteoblast differentiation program. 
 
Particularly intriguing in the osteoblast lineage tracing study discussed above was the finding 
that the entry of the osteoprogenitors into the primary ossification center coincided with the 
initial invasion by blood vessels of the intermediate avascular cartilage tissue (Maes et al., 
2010c). The labeled Osx/LacZ+ cells co-migrated along with the neovascularization front, 
with some of them intimately associating with the cartilage-invading blood vessels, being 
wrapped as pericytes around the endothelium (Figure 3) (Maes et al., 2010c). The molecular 
underpinnings of this phenomenon are not yet understood. A plausible hypothesis is that the 
coinciding movement of perichondrial osteoprogenitors and blood vessels into developing 
bones is triggered by common chemo-attractants, emanating from the degrading late-
hypertrophic cartilage matrix and directionally steering the osteo-angiogenic co-invasion. 
Multiple factors that may be involved in the attraction of osteoblast and/or their precursors to 
sites in need of new bone formation have been identified. These include chemotactic growth 
factors that are released, activated or produced at sites of tissue resorption, and in many cases 
also have angiogenic properties. A second possible hypothesis, and not mutually exclusive, is 
that interactions between osteoblast lineage cells and endothelial cells determine the joint 
processes of angiogenesis and osteoprogenitor trafficking into the bone.  
The current knowledge on chemo-attractants for osteogenic cells, on the control of osteoblast 
lineage cell recruitment to sites of active bone formation, and on the regulation of osteo-
angiogenic coupling is reviewed here. 
 
 
CONTROL OF OSTEOBLAST RECRUITMENT AND BONE FORMATION 
DURING DEVELOPMENT AND REMODELING BY CHEMOTACTIC AND 
OSTEO-ANGIOGENIC COUPLING FACTORS 
 
As mentioned above, during bone development there is a clear spatial-temporal phase to be 
discriminated where osteogenic cells travel from the outer perichondrium to the developing 
primary ossification center inside the bone. Cell migration is a dynamic process that requires 
the coordinated formation and disassembly of focal adhesions and re-arrangements of the 
actin cytoskeleton. Although the underlying mechanisms are still poorly understood and will 
not be covered here, there is evidence that the osteoprogenitors are attracted, together with 
blood vessels, by chemotactic factors released from the mold. But also in the adult skeleton, 
when bone is being constantly remodeled, osteoblasts or their precursors need to be recruited 
to the active bone surfaces. This phase in the remodeling cycle is not only imperative for bone 
health, but may also bear promising potential towards the development of therapeutic 
strategies for conditions where anabolic stimulation of bone formation is sought, such as in 
osteoporosis. Intriguingly, a tight correlation between ossification and vascularization of bone 
remains evident, also in remodeling bones beyond the stages of development and growth. 
Recent data have started to identify some key factors that may be involved in the regulation of 
osteogenic cell chemo-attraction and in the orchestrated interplay between osteoblast 
recruitment and functioning and angiogenic processes. 
 
Growth factors inducing chemotaxis of osteoblast lineage cells in vitro 
 
Recruitment of osteoblast lineage cells to the sites programmed for ossification or in need of 
new bone formation conceivably relies on precisely controlled temporal and spatial 
chemotactic navigation signals. There are multiple candidate guidance cues that may be 
involved in the directional migration of osteoblast and/or their precursors. In vitro, several 
factors with chemotactic potential towards osteoblasts and their precursors have been 
identified (see Table 1). These include, but are not restricted to, constituents of the bone 
matrix such as fragments of collagen or osteocalcin, complement fragments, inflammatory 
cytokines and growth factors that are typically released, activated or produced at sites of 
matrix resorption (also see below). In this section we will focus primarily on the secreted 
growth factors, which have been studied most intensively. Examples include platelet derived 
growth factor (PDGF), vascular endothelial growth factor (VEGF) and its homologue 
placental growth factor (PlGF), and transforming growth factor β (TGF-β) (see Table 1 and 
references therein). Among their many other effects on mesenchymal stem and progenitor 
cells and osteoblasts (such as affecting their proliferation, lineage determination and 
differentiation, survival, and/or activity), they are potent inducers of osteogenic cell migration 
in vitro. The effect on cell motility induced by these soluble factors is typically assessed using 
trans-membrane Boyden chamber systems (also referred to as transwell assays, testing 
chemotactic attraction of cells cultured on a perforated membrane in an upper well towards a 
substance added to the lower well) or in vitro wound healing assays (‘scratch’, ‘2D cell 
migration’, or ‘gap-closure’ assay). Osteogenic cells from a variety of sources and at different 
levels of osteoblastic differentiation have been tested for their chemotactic responses to these 
growth factors, as listed in Table 1. 
PDGF is a major mitogenic agent for mesenchymal cells, primary osteoblasts and various 
osteoblastic cell lines (Abdennagy et al., 1992, Canalis et al., 1992). In addition, PDGF 
(particularly PDGF-BB) was found to be a powerful chemotactic factor for mesenchymal 
cells and osteogenic cells in vitro (see Table 1). PDGF exists as various isoforms (AA, AB, 
BB, CC and DD), which can bind with different affinities to dimerized receptors consisting of 
two subunits (PDGFRα and PDGFRβ) that assemble either in a homotypic or heterotypic 
manner. Both receptor subunits are expressed on the cell surface of osteoblasts and their 
precursors. Chemotactic activity has been reported for PDGF-AA, -BB and -AB, whereas 
PDGF-CC had no effect (for references, see Table 1). PDGF- DD, the newest member of the 
family, is not highly expressed in bone and its role in herein remains unclear. 
 
The migration capacities of mesenchymal cells appear in vitro to change during osteogenic 
differentiation: migration is generally highest at early differentiation stages and gradually 
decreases during later differentiation while adhesiveness increased (Ichida et al., 2011). This 
is essentially in line with the abovementioned in vivo study using stage-specific osteoblast 
lineage cell tracing in which specifically osteoblast precursors, and not mature osteoblasts, 
were found to migrate from the perichondrium to the developing bone center (Maes et al., 
2010c). There are, however, exceptions: while cultured undifferentiated osteoblasts are more 
sensitive to PDGF-BB, BMP-2 and BMP-4, more mature osteoblasts were found to respond 
better to TGF-β1 and bFGF. This may be related to the differently regulated expression of the 
various receptors during osteoblastogenesis. For instance, it has been reported that expression 
of PDGFRα and PDGFRβ decrease with differentiation of MC3T3-E1 cells (Beck et al., 
2001, Fiedler et al., 2004, Sanchez-Fernandez et al., 2008), while several FGF receptors 
increase (Beck et al., 2001, Haupt et al., 2009). 
 
In contrast to PDGF, whose in vivo role in the skeleton has not been elucidated, VEGF, PlGF, 
and TGF-β have been thoroughly studied using in vivo models. VEGF is well established as 
an important regulator of skeletal angiogenesis and osteoblast differentiation, as will be 
described in-depth in the next section. Of the greater VEGF family (consisting of VEGF-A 
(referred to as VEGF) to VEGF-E and PlGF, a homologue acting via VEGFR1 or Flt-1, one 
of the main tyrosine kinase VEGF receptors), several members have been shown to exert 
chemotactic effects on mesenchymal progenitor cells and osteoblastic cells in vitro (for 
references, see Table 1). Hence, VEGF represents an outstanding candidate to induce 
concomitant migration of osteoprogenitors and endothelial cells. Such a combined 
chemotactic effect may perhaps provide partial explanation of the phenomenon of osteogenic-
angiogenic coupling (see below). 
 
TGF-β  and a number of BMPs (which belong to the larger TGF-β family) are also well 
documented to induce osteoblast cell migration and differentiation (Table 1). Moreover, as 
discussed next, TGF-β was elegantly shown to be important for osteoblast recruitment to bone 
remodeling sites in vivo (Tang et al., 2009). 
 
Osteoblast recruitment during bone remodeling in vivo 
Bone is an extremely dynamic tissue; throughout life, it goes through continuous cycles of 
osteoclastic resorption and osteoblastic formation of new bone matrix. This process of bone 
remodeling is needed to remove older matrix and cells and stress-induced microcracks, in 
order to maintain the integrity and biomechanical stability of the skeleton, and to regulate 
mineral homeostasis of the whole organism. Bone remodeling takes place at multiple sites 
throughout the skeleton at each given time, in entities called Bone Remodeling Units (BRU). 
A given BRU typically consists of osteoclasts that initiate the bone remodeling by removing 
old bone matrix, and osteoblast lineage cells that subsequently become activated to lay down 
new bone. Four phases are discriminated in the bone remodeling cycle: the phases of 
activation, resorption, reversal and formation. In the first phase, hematopoietic osteoclast 
precursors proliferate, fuse, differentiate and become activated to form active multinucleated 
mature osteoclasts; this process is regulated by the combined action of macrophage-colony 
stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand 
(RANKL), both expressed by osteoblast lineage cells (see below) (Sims and Gooi, 2008, 
Henriksen et al., 2009). Once osteoclasts are activated, resorption starts by the local secretion 
of HCl via H+-ATPase proton pumps and chloride channels to lower the pH, and by the 
release of resorbing enzymes to digest the old bone. In the reversal phase, osteoclast activity 
ceases and osteoblast precursors are recruited to the BRU, where they differentiate to mature, 
cuboidal osteoblasts that adhere to the bone surface (Sims and Gooi, 2008, Henriksen et al., 
2009). During the subsequent formation phase, the differentiated osteoblasts deposit new 
bone matrix that becomes mineralized. Osteoblasts that become entrapped within the matrix 
further differentiate to osteocytes; these cells play important roles in mechano-sensing and the 
regulation of bone remodeling (Bonewald, 2011). 
 
This 4-stage process of bone remodeling needs to be well balanced and tightly controlled to 
maintain a normal bone mass. Failure of this homeostatic skeletal turnover is one of the most 
common early manifestations of aging. In pathologies characterized by an increased bone 
turnover, osteoblastic bone formation cannot compensate for the rapid osteoclastic resorption. 
A higher rate of bone remodeling with a net bone loss is the most prevalent mechanism 
underling the development of widespread low bone mass disorders such as osteoporosis. The 
most typical and frequent cause of osteoporosis is the postmenopausal decline in estrogen 
levels in elderly women. Estrogen deficiency increases both the number of sites at which 
remodeling is initiated, and the extent of resorption at a given site. The most routinely used 
therapies against osteoporosis are anti-catabolic drugs that effectively inhibit osteoclastic 
bone resorption, but there is a great clinical demand for anabolic treatments that increase bone 
formation (Baron and Hesse, 2012, Rachner et al., 2011) (see further).  
One potential way to increase osteoblast activity on the bone surface and improve bone 
formation could be by stimulating the recruitment of osteoblast precursors towards the bone 
surfaces and bone resorptive sites. During normal bone remodeling, the activities of both 
osteoclasts and osteoblasts are ‘coupled’ such that the resorption and formation of bone are 
balanced and the net bone mass is maintained. This balance implies the existence of 
mechanisms tightly coordinating the differentiation of osteoblasts and osteoclasts as well as 
their migration to locations where they function. On the one hand, cells of the osteoblasts 
lineage directly control osteoclastogenesis and bone degradation, by virtue of the expression 
of the necessary osteoclastogenic signals M-CSF and RANKL in bone marrow stromal cells 
(BMSCs), osteoblasts, and osteocytes (Sims and Gooi, 2008, Henriksen et al., 2009, 
Nakashima et al., 2011). Conversely, osteoclasts are thought to reciprocally stimulate 
osteoprogenitor recruitment and osteoblast differentiation to initiate the anabolic arm of the 
remodeling process. With regard to the induction of osteogenic cell recruitment, it is assumed 
that the process of osteoclastic resorption of the bone matrix mediates the local release of a 
myriad of growth factors that are stored in the extracellular matrix, which can subsequently 
act as potent stimuli of osteoprogenitor chemotaxis and thereby couple bone resorption to 
bone formation. Growth factors like TGF-β, BMPs, IGFs, VEGF and PDGF, discussed above 
for their potency to attract osteoblastic cells and/or progenitors, are known to have strong 
affinity for extracellular constituents of bone and to be partly sequestered into the bone matrix 
after their secretion (Sims and Gooi, 2008). The study by Tang et al. (Tang et al., 2009) 
provided the first in vivo proof of this longstanding hypothesis by indicating that TGF-β, 
released from bone matrix during osteoclastic bone matrix degeneration, exerts a chemotactic 
effect on osteoblast precursors to these bone resorptive sites. In particular, the authors showed 
that medium conditioned by a culture of osteoclasts on bone slices induced migration of 
BMSCs in vitro, largely mediated via TGF-β1; TGF-β promoted BMSC migration and 
lamellopodia formation through SMAD signaling. Mice lacking TGF-β1 showed disturbed 
bone remodeling with decreased trabecular bone volume and thickness, increased trabecular 
separation, and the presence of fewer osteoblasts on the trabecular bone surfaces at 3 months 
of age. Most notably, injected osteogenic BMSCs that were labeled with GFP were found to 
home to the trabecular bone surfaces in WT mice, whereas only very few injected BMSCs 
migrated to bone resorptive sites in TGF-β knockout mice (Tang et al., 2009). 
In addition to chemotactic signals released from the matrix upon resorption, osteoclasts can 
also play a direct role in regulating osteoblast recruitment. For instance, osteoclasts 
themselves secrete factors with chemotactic properties such as PDGF (Sanchez-Fernandez et 
al., 2008), and they can signal directly to cells of the osteoblast lineage through cell-bound 
molecules (Sims and Gooi, 2008, Henriksen et al., 2009). In a recent paper evidence was 
provided that osteoclast-produced semaphorin 4D (Sema4D, a predominantly transmembrane 
protein previously known as axon-guidance molecule) contributes to balanced remodeling in 
adult bone by binding to its receptor Plexin-B1, expressed on osteoblasts (Negishi-Koga et 
al., 2011). This interaction in fact appears to repel osteoblasts from osteoclasts at bone 
resorptive sites, thus suppressing bone formation during the bone resorption phase. Mice 
lacking Sema4D or Plexin-B1 or both showed increased bone volume, trabecular thickness 
and bone strength, resulting from increased osteoblastic bone formation. Although the fine 
details of the underlying mechanism remain to be clarified, activation of the small GTPase 
RhoA and its downstream kinase ROCK seem to be implicated in the Sema4D-induced 
inhibition of osteoblast differentiation and stimulation of cell motility (Negishi-Koga et al., 
2011). 
New insights in the mechanisms underlying the induction of the reversal phase, during which 
osteoblasts are recruited to the BRU, may eventually lead to the development of novel 
therapeutic targets to treat osteoporosis. 
 
 
Bone formation is coupled to vascularization: regulation by hypoxia signaling and 
VEGF 
 
The recruitment of osteoprogenitors into new bone centers forming via endochondral 
ossification, both in developing and healing bones, coincides with neovascularization of the 
cartilage intermediate (Maes et al., 2010c). Also intramembranous bone formation occurs is 
tightly associated with angiogenesis and vascularization of the forming bone. Moreover, 
mature bone is highly vascularized, and the lifelong process of bone remodeling in the BRUs 
occurs in close proximity of the blood vessels of the bone and bone marrow environment. 
Reduced blood flow has been linked to old age and low bone mass disorders such as 
osteoporosis, and to impaired fracture healing (see below) (Andersen et al., 2009, Lafage-
Proust et al., 2010, Maes, 2013, Burkhardt et al., 1987). 
This close spatial and temporal association of bone formation with vascularization, which is 
well recognized in virtually all settings of ossification, has been termed ‘angiogenic-
osteogenic coupling’ (Schipani et al., 2009, Wan et al., 2010). The reasons that the vascular 
system is crucial for bone formation during skeletal development, maintenance and repair 
obviously include its intrinsic function to supply the necessary oxygen, nutrients and growth 
factors/hormones to the bone cells. The blood vessels also deliver hematopoietic precursors of 
osteoclasts to sites of cartilage and bone resorption and remove end products of the 
extracellular matrix degradation. In addition, the vasculature likely serves to bring in 
progenitors of osteoblasts for subsequent bone depositing. For instance, the subendothelial 
wall of skeletal blood vessels contains pericytic cells consistent with osteoprogenitors in 
terms of molecular profile and osteoblastic differentiation potential; this could well offer part 
of the cellular explanation for the coupling paradigm between angiogenesis and osteogenesis 
(Maes et al., 2010c, Sacchetti et al., 2007). Molecularly, the precise mechanisms of 
angiogenesis and its coupling with osteogenesis during bone development, fracture healing 
and bone remodeling are not completely understood, but studies using a variety of genetic 
mouse models identified VEGF and hypoxia signaling components as key players of 
angiogenic-osteogenic coupling (Table 2) (Schipani et al., 2009, Maes et al., 2012b, Riddle et 
al., 2009). 
 
 
Regulation of bone vascularization by VEGF: lessons from genetically modified mouse 
models  
Vascularization is an absolute requirement for bone development, growth, repair and 
homeostasis. This is particularly evident during endochondral ossification processes: the 
cartilage intermediate remains as an avascular mesenchymal tissue until the chondrocytes 
reach a fully differentiated state of hypertrophy. Terminal hypertrophic cartilage undergoes 
angiogenic invasion, a process that is associated with the decay of the cartilage matrix and its 
replacement by bone. During development, three consecutive vascularization stages can be 
delineated that altogether cover the replacement of the avascular cartilage template by highly 
vascularized bone and marrow tissue (see Figures 1 and 3) (Maes, 2013). First, the initial 
vascular invasion of the cartilage anlagen in the early embryo involves endothelial cells 
invading from the perichondrial tissues and organizing into immature blood vessels in the 
primary center of ossification. Second, capillary invasion at the metaphyseal border of the 
growth cartilage mediates rapid bone lengthening. Third, vascularization of the cartilage ends 
initiates the formation of secondary ossification centers. Each of these vascularization events 
is closely followed by ossification in the respective area (the primary ossification center, 
trabecular bone formation at the metaphyseal chondro-osseous junction, and the secondary 
ossification center, respectively). Hence, the vascularization of the expanding bone centers is 
a crucial aspect of bone development and growth. Early in vivo experiments exposed the 
importance of the vasculature to growing bones by inducing physical blockage of the bone’s 
blood supply, resulting in reduced longitudinal growth (Trueta and Morgan, 1960). 
Molecularly, VEGF (VEGF-A) is one of the most powerful and critical mediators of 
angiogenesis. The deletion of even a single copy of the Vegf gene results in early embryonic 
lethality owing to defective vascular development. Five VEGF isoforms have been identified 
in humans, while there are three major isoforms in the mouse (VEGF120, VEGF164, and 
VEGF188). VEGF binds to and activates two tyrosine kinase receptors, VEGFR1 (Flt-1) and 
VEGFR2 (KDR/Flk-1), which regulate both physiological and pathological angiogenesis. In 
addition, neuropilins (NRP1 and NRP2) can act as co-receptors for specific VEGF isoforms 
(Yla-Herttuala et al., 2007). 
In endochondral bones, VEGF is expressed abundantly by late hypertrophic chondrocytes, 
where it is critical for blood vessel invasion and replacement of cartilage by bone. This was 
first shown by the inhibition of VEGF action in juvenile (24-day-old) mice via administration 
of a soluble VEGF receptor chimeric protein (mFlt (1-3)-IgG or sFlt-1): vascular invasion of 
the growth plate became impaired and concomitantly, trabecular bone formation and bone 
growth were reduced. Also, the hypertrophic cartilage zone became enlarged, likely due to 
reduced osteoclast-mediated resorption (Gerber et al., 1999). Further studies performed over 
the last decade using genetically modified mice have univocally established that VEGF is an 
essential physiological mediator of all 3 key vascularization stages of endochondral bone 
development. Given the fact that a full knockout of VEGF led to early lethality even in the 
heterozygous state, several alternative mutagenesis approaches have been and are being 
exploited to investigate the role of VEGF in the skeleton. These models include the 
Cre/LoxP-mediated conditional inactivation of the VEGF gene (Vegfa) in specific skeletal 
cell subsets, genetically engineered mice expressing only one of the 3 major VEGF isoforms, 
and transgenic over-expression strategies making use of temporal and/or tissue-specific 
mutagenesis. Table 2 gives an overview of studies employing genetic mouse models of 
perturbed expression of VEGF family members in the skeleton and their phenotypic outcome 
(see Table 2 and references therein). 
Altogether, these models have exposed multiple essential roles of VEGF and its isoforms in 
endochondral ossification, not only as key inducer of vascularization but also as a direct 
modulator of bone development by affecting the various cell types involved. Mesenchymal 
stem and progenitor cells, perichondrial cells, osteoblasts and osteoclasts all express both 
VEGF and VEGF receptors and respond to VEGF signaling by enhanced recruitment, 
differentiation, activity and/or survival (reviewed in (Maes, 2013, Dai and Rabie, 2007)). 
These pleiotropic actions of VEGF on the various cells in the bone environment contribute to 
the tight coordination of vascularization, ossification, and matrix resorption in endochondral 
ossification. The current model (see Figure 3) is that VEGF is produced at low levels by 
immature chondrocytes, where it stimulates chondrocyte survival at least in part by inducing 
perichondrial vascularization. VEGF is also produced at high levels by hypertrophic 
chondrocytes and is partly sequestered in the cartilage matrix upon its secretion. Trapped 
VEGF (hence, particularly the isoforms that have high matrix-binding affinity, such as 
VEGF164 and VEGF188) can be released from the matrix by proteases like matrix 
metalloproteinase (MMP)-9, secreted by osteoclasts/chondroclasts during cartilage resorption. 
VEGF can then bind to its receptors on endothelial cells and stimulate the directional growth 
of angiogenic blood vessels to invade the hypertrophic cartilage, which may be indirectly 
associated with an increased potential delivery of osteoblast and osteoclast progenitors. The 
osteoblasts or their precursors in this region are also affected by the VEGF signaling in their 
recruitment, proliferation, differentiation and/or function. At the same time, VEGF directly 
works as a chemo-attractant stimulating osteoclast invasion of cartilage and enhancing 
osteoclast differentiation, survival and resorptive activity, thereby creating a positive feedback 
system through the release of more matrix-bound VEGF from the cartilage that is being 
resorbed (reviewed in (Maes, 2013)). 
The role of VEGF as a prime mediator of angiogenic-osteogenic coupling was revealed in 
most or all of the mutant mouse models listed in Table 2. Reduced VEGF signaling was 
shown to reduce both vascular density and bone formation in loss-of-function mice (Maes et 
al., 2002, Gerber et al., 1999). Conversely, temporal VEGF over-expression in the skeleton 
induced combined hyper-vascularization and increased bone formation during development 
and in adult mice (Maes et al., 2010b). Besides the indirect, vascularization-mediated 
influences on bone formation, direct VEGF-effects on osteogenic cells also contribute to the 
coupling. Although the relative importance of these aspects is extremely difficult to delineate 
in vivo, several in vitro studies provided evidence for cell-autonomous roles of VEGF 
signaling in stimulating chemotactic migration of osteogenic cells (see Table 1) and affecting 
osteoblastic proliferation and differentiation (Hah et al., 2011, Mayer et al., 2005, Grellier et 
al., 2009). In addition to autocrine and paracrine signaling of extracellular VEGF, intracellular 
VEGF was recently implicated to act via intracrine ways in osteogenic cells (Liu et al., 2012). 
Conditional deletion of VEGF in osteoprogenitors induced an osteoporosis-like phenotype 
characterized by reduced bone mass and increased bone marrow fat. VEGF knockdown in 
cultured BMSCs further revealed that osteogenic differentiation was reduced in the absence of 
intracellular-acting VEGF, to the benefit of adipogenesis. Thus, intracrine VEGF plays a role 
in the regulation of the balance between osteoblast and adipocyte differentiation (Liu et al., 
2012). 
 
The actions of VEGF, also in the skeleton, are highly dose-dependent, and its physiological 
levels must be under very strict control mechanisms. Several hormones (including PTH, GH, 
1,25(OH)2D3), locally produced growth factors (e.g. FGFs, TGF-β, BMPs, IGFs, PDGF), and 
skeletal transcription factors (including Runx2 and Osx) have been implicated in the 
regulation of VEGF expression (Tang et al., 2012, Maes, 2013, Dai and Rabie, 2007). One of 
the best-characterized regulatory mechanisms upstream of VEGF expression, in general and 
in skeletal tissues, is hypoxia signaling via the hypoxia-inducible factor (HIF) pathway. 
 
HIF pathway involvement in osteo-angiogenic coupling 
Cellular oxygen-sensing mechanisms play major roles in pathological settings such as cancer 
and ischemia, and in normal development and homeostasis. HIFs (HIF-1 and HIF-2) are 
ubiquitously expressed transcription factors that modulate gene expression to mediate cellular 
responses and adaptation in hypoxic environments; typical targets include genes involved in 
glucose utilization and cell metabolism (stimulating anaerobic glycolysis), angiogenesis (for 
instance by inducing VEGF expression, a direct target of HIF-1), and erythropoiesis (through 
increased erythropoietin (EPO) production) (Semenza, 2012). HIFs are heterodimers 
consisting of an α-subunit, which is regulated by oxygen, and a β subunit that is constitutively 
expressed in an oxygen-independent manner. When sufficient oxygen is available, HIF-1α (as 
well as HIF-2α) becomes hydroxylated on specific amino-acid residues within its oxygen-
dependent degradation domain (ODD) by prolyl hydroxylases. This hydroxylation renders 
HIF-1α to be recognized by the Von Hippel-Lindau protein (pVHL), an E3 ubiquitin ligase, 
and targeted for degradation in the proteasome. VHL thus functions as an upstream negative 
regulator of HIF, by affecting protein stability. In hypoxic conditions this hydroxylation of 
HIF-1α does not occur, and HIF-1α protein can accumulate, translocate to the nucleus, 
dimerize with HIF-1β, and bind to hypoxia response elements (HRE) within the promoters of 
its hypoxia-responsive target genes (Semenza, 2012).  
 
Hypoxia too is one of the drivers of the tight coupling between angiogenesis and osteogenesis 
in skeletal tissues, at least in part through induction of VEGF. Hypoxia is a strong trigger of 
VEGF expression in chondrocytes, osteoblasts, and possibly osteoclasts, through mechanisms 
that involve HIF both in vitro and in vivo (see (Schipani et al., 2009, Riddle et al., 2009, Maes 
et al., 2012b)). The role of HIF pathway components in the skeleton has been studied using a 
growing collection of mutant mouse models, primarily Cre-loxP-mediated conditional 
knockouts (listed in Table 2). Their functioning as key regulators of osteo-angiogenic 
coupling in adult bone was first revealed in a study by Wang et al (Wang et al., 2007), who 
generated VHL and HIF-1α conditional knockout mice using a Cre recombinase expressed 
under the control of the osteocalcin gene promoter, expressed in differentiated osteoblasts. 
Upon disruption of the Vhl gene, HIFs were stabilized and the level of VEGF expression 
increased. Micro-CT analysis showed a massive increase in bone volume and osteoblast 
number and a decrease in trabecular separation. In vitro, osteoblast differentiation was not 
altered upon VHL inactivation and no changes in proliferation rate and apoptosis were 
detected, suggesting that osteoblastic HIFs may exert their effect in a cell-nonautonomous 
manner. The increase in bone mass was associated with a proportional increase in vascular 
density, correlating with upregulation of VEGF. The opposite phenotype was observed when 
HIF-1α was inactivated in mature osteoblasts. A double knockout of VHL and HIF-1α still 
caused vascular effects similar to those in the VHL knockout mice as well as a milder but 
evident increase in trabecular and cortical bone mass, which was attributed to HIF-2α taking 
over the function of HIF-1α in its absence, to enhance VEGF production and drive 
angiogenesis (Wang et al., 2007). As such, this study allocated a central role to HIF-1α in 
coupling angiogenesis to osteogenesis during endochondral ossification. In a more recent 
study, the promoter of the earlier osteogenic marker Osx was used to direct a conditional 
knockout of VHL, leading to the discovery of a role for HIF signaling (predominantly through 
HIF-2) in osteoprogenitors in controlling hematopoiesis, particularly red blood cell 
production, in an EPO-dependent manner. Indeed, inactivation of VHL in osteoprogenitors 
led to increased EPO expression in bone and selective expansion of the erythroid lineage, 
while inactivation of HIF-2α, but not HIF-1α, reduced EPO expression in bone (Rankin et al., 
2012).	   Thus, osteoblast lineage cells emerged as important regulators of the coupling by 
sensing oxygen tension and directing adjustments in vascularization and oxygen supply to 
meet their demands for optimal ossification (Schipani et al., 2009, Maes et al., 2012b, Maes, 
2013, Riddle et al., 2009). 
 
The hypoxia-inducible cascade, particularly HIF-1α and VEGF, also plays critical roles in the 
early development of the long bones (Figure 3). Both have been implicated in the initial 
osteo-angiogenic co-invasion of developing bones in vivo and in osteogenic cell migration in 
vitro. Immature chondrocytes in the early endochondral cartilaginous condensations are 
resistant to vascular invasion due to the production of angiogenic inhibitors, such as 
chondromodulin-I, troponin-I and thrombospondins (see (Maes, 2013)). As a result, the 
chondrocytes of the long bone anlagen and fetal growth plates experience hypoxia (Schipani 
et al., 2001, Maes et al., 2004). The chondrocytes are capable to survive and proliferate and 
differentiate in this hypoxic environment, at least in part via HIF-regulated adaptation 
mechanisms to oxygen deprivation (Maes et al., 2012a, Schipani et al., 2001). Inactivation of 
HIF in chondrocytes causes cell death due to the inability of the cells to switch to vital 
oxygen-sparing metabolic pathways (HIF-dependent activation of anaerobic glycolysis), and 
by the lack of sufficient blood vessel accumulation in the perichondrium immediately 
surrounding the cartilage (VEGF-dependent angiogenesis). In mice over-expressing VEGF 
(Col2-Cre mediated VEGF164 conditional transgenic) osteo-angiogenic invasion of 
developing bone centers occurred prematurely and excessively, with aberrant bone deposition 
in this vascularized area leading to misshapen limbs (Maes et al., 2010b). Conversely, the 
invasion process and primary ossification center formation was delayed in mice lacking HIF-
1α or VEGF in cartilage, which could be rescued by forced VEGF164 over-expression in the 
combined mutant (in contrast to the cell death of HIF-deficient chondrocytes that could only 
be partially rescued) (Maes et al., 2012a). These findings strongly suggest that hypoxia-
induced, HIF-mediated VEGF expression in cartilage is required for the concomitant 
recruitment of angiogenic blood vessels and osteoprogenitors into developing endochondral 
bone centers (Figure 3). As mentioned previously, VEGF is chemo-attractive for MSCs and 
osteoblastic cells in vitro. Besides VEGF also several other growth factors, including PDGF 
and TGF-β, have both angiogenic properties and chemotactic effects on osteogenic cells, 
which could provide partial explanation of osteogenic-angiogenic coupling by a mutual 
attraction of endothelial cells and osteoprogenitors. These signals are also produced by 
osteoblast lineage cells themselves, implicating a complex crosstalk between the two cell 
types in the interplay between osteogenic cell recruitment to new sites of bone formation and 
vascular invasion and expansion. Moreover, hypoxia signaling by downstream mechanisms 
other than VEGF has also been shown to affect the migration properties of MSCs. 
Conditioned medium of MSCs cultured in hypoxic conditions stimulated MSC migration 
more than medium of normoxic cultures (Annabi et al., 2003). The medium of hypoxic 
osteocytes also significantly increased MSC migration, which was attributed to the 
chemotactic effect of hypoxia-induced osteopontin, acting possibly via one of its receptors, β1 
integrin (Raheja et al., 2008). Integrins are important in cell-matrix adhesion; in hypoxic 
conditions their expression patterns are altered and associated with increased migration of 
hMSCs (Saller et al., 2012). Although many studies show a positive correlation between 
hypoxia and migration (Raheja et al., 2008, Saller et al., 2012, Vertelov et al., 2013), some 
controversy exists. Some studies demonstrate an increased activation of RhoA GTPases in 
hypoxic conditions with enhanced targeted migration of MSCs (Vertelov et al., 2013) while 
others negatively correlate hypoxia with MSC migration through modulation of RhoA activity 
(Raheja et al., 2011). Further in vitro and in vivo studies will be required to decipher the 
mechanisms of osteogenic cell migration and recruitment that are regulated by the hypoxia 
signaling pathway and VEGF. 
 
In conclusion, several molecules have been related to aspects of osteogenic cell recruitment to 
sites of bone formation and the close coupling of ossification with angiogenic processes. The 
interactions that tune these orchestrated processes are however still incompletely understood. 
The interplay between osteogenic cells and endothelial cells is complex and reciprocal, in that 
the cells of bone on the one hand depend on the signals, oxygen, and cellular precursor 
delivery via the blood stream, while on the other hand they influence the vascular 
arrangement and function, for instance through oxygen sensing and angiogenic signaling. The 
characterization of the molecular machinery controlling these intricate processes relied 
heavily on the use of mutant mice over the last decade, and its future refinement will depend 
on the further optimal use of genetic tools to target genes in specific cells and developmental 
time points. Elucidating further the functional relevance and molecular regulation of 
osteogenic cell migration and angiogenic-osteogenic coupling mechanisms represents a major 
challenge, with high potential to offer novel therapeutic avenues for bone diseases and bone 
regeneration strategies. 
 
 
RECAPITULATION OF EMBRYONIC MECHANISMS DURING 
ENDOCHONDRAL BONE REPAIR: OSTEOBLAST RECRUITMENT COUPLED 
TO NEOVASCULARIZATION 
 
Unlike soft tissues, which repair predominantly through the production of fibrous scar tissue 
at the site of the injury, the skeleton possesses an astounding capacity to regenerate upon 
damage. Bone defects heal by forming new bone that is indistinguishable from adjacent, 
uninjured bone tissue. It has been appreciated for a long time that fracture repair in the adult is 
a multi-step process that bears close resemblance to fetal skeletal tissue development, with 
both intramembranous and/or endochondral bone formation processes occurring depending on 
the type of fracture (Schindeler et al., 2008, Beamer et al., 2009). In recent years this close 
resemblance has been supported by genetic and molecular studies showing that similar 
pathways are at work in both settings (Gerstenfeld et al., 2003, Ferguson et al., 1998), 
although additionally, some signaling molecules that are dispensable for development become 
important during fracture repair (Maes et al., 2006, Tsuji et al., 2006). 
 
Following bone injury, a hematoma is formed, platelets are activated and degranulate, and 
acute inflammatory cells and macrophages are recruited to the fracture site. These early 
inflammatory responses are associated with the release of a plethora of growth factors, 
including PDGF, VEGF, TGF-ß, BMPs, FGFs, and IGFs and cytokines such as TNF-α and 
interleukins (Ferguson et al., 1998, Gerstenfeld et al., 2003, Schindeler et al., 2008). These 
signals have important roles in the initiation of the repair process, most likely including in the 
recruitment of cells with osteogenic potential to repair the defect as several of them have 
established chemotactic potential in vitro (see Table 1). While the blood clot is being 
stabilized, new blood vessels begin to form by endothelial cells from the periosteal vessels 
and surrounding muscles. Mesenchymal progenitor cells are recruited to repopulate the site of 
injury and differentiate into chondrocytes (particularly in the internal callus, i.e. domains 
distant from ingrowing capillaries) or into osteoblasts (predominantly in subperiosteal areas 
creating a hard external callus bridging the fracture gap via intramembranous ossification). 
The (fibro-)cartilage in the soft callus is gradually replaced with immature woven bone, that 
in the final phase of the healing process is remodeled by the actions of osteoclasts and 
osteoblasts, ultimately restoring the pre-injury shape, strength and function of the bone 
(Figure 4). 
Like in developing bones, recruitment of osteogenic progenitor cells to the site of new bone 
formation in the adult setting of endochondral bone repair occurs in close association with 
neovascularization of the cartilaginous callus tissue (Maes et al., 2010c). In further 
resemblance of the embryonic perichondrial progenitor cell source, adult Osx-expressing 
osteoprogenitors were markedly abundant in the peripheral portion of the callus initially, 
apparently originating from the periosteum and migrating inwards (Maes et al., 2010c). 
Lineage analyses have shown before that the periosteum is a crucial source of osteoblasts and 
chondrocytes for fracture repair, along with the bone marrow neighboring the callus 
delivering MSCs to the site (Colnot, 2009). Circulating stem cells or bone marrow cells 
recruited from distant bones can also be attracted to sites of bone repair or regeneration, for 
instance by the CXCR4/stromal cell-derived factor-1 pathway, but their contribution to 
normal healing processes is still to be clarified (Pignolo and Kassem, 2011, Otsuru et al., 
2008, Taguchi et al., 2005). For therapy, bone marrow derived MSCs are among the most 
patent sources of cells for human therapy, although periosteal cells have gained a lot of 
interest as promising population for applications in tissue engineering and bone regeneration 
settings (Bueno and Glowacki, 2009, Khosla et al., 2010). 
 
As the co-invasion of healing bone centers by osteoblast lineage cells and angiogenic blood 
vessels was studied by confocal microscopy, again their close juxtaposition and the pericytic 
behavior of a subset of the translocating osteoprogenitors were observed (Maes et al., 2010c) 
(Figure 4). Neovascularization of cartilage precedes new bone formation in defects that heal 
via endochondral ossification and is an essential aspect of successful bone repair; failure to 
restore the vascular network delays or impairs bone healing, as prevalently associated with 
advanced age and disorders such as diabetes (Schindeler et al., 2008, Beamer et al., 2009, 
Lienau et al., 2009). Among many crucial bone-anabolic stimuli brought to the callus by the 
blood vessels, it will thus be of great interest to elucidate how the vasculature provides a 
conduit for entry of osteoprogenitor cells in the callus and whether this occurs through similar 
mechanisms as those operating in fetal life (Maes et al., 2010c, Khosla et al., 2010, Kumar 
and Ponnazhagan, 2012). Most or all of the chemotactic and osteo-angiogenic signals 
discussed previously in this review and listed in Table 1, are present in the fracture callus. 
Moreover, the vascular damage following injury of bone disrupts the blood flow, and leads 
the fracture site to become extremely hypoxic, further boosting VEGF expression. VEGF is 
strongly increased locally in the fracture hematoma and is also systemically elevated in 
injured patients (Beamer et al., 2009). Inhibition of endogenous VEGF activity, by 
sequestration or VEGF receptor blockade, inhibited bone repair and resulted in non-unions in 
experimental loss-of-function models (Jacobsen et al., 2008, Street et al., 2002). As in 
development, VEGF secretion in the bone environment attracts blood vessels and stimulates 
endothelial cells to form new blood vessels, which is likely indirectly associated with an 
increased potential delivery of mesenchymal stem or progenitor cells with osteogenic 
potential, from extraluminal sources and/or fracture-mobilized circulating cells (Khosla et al., 
2010, Kumar and Ponnazhagan, 2012, Pignolo and Kassem, 2011). VEGF signaling can also 
directly stimulate the recruitment and differentiation of osteoblasts, bone formation can be 
further enhanced by endothelial production of osteogenic differentiation factors, such as 
(VEGF-induced) BMP-2 (Bouletreau et al., 2002). The presence or absence of a functional 
vascular bed may, along with and probably in part determined by the mechanical stability of 
the fracture, also determine mesenchymal stem cell fate decisions. Instable, hypoxic fractures 
appear to favor the formation of avascular cartilage and healing via an endochondral 
ossification process. In contrast, when stabilization of the bone segments is sufficient, healing 
occurs primarily through intramembranous ossification, feasibly supported by the vascular 
delivery of oxygen, nutrients and trophic factors that permit direct differentiation of 
mesenchymal cells into osteoblasts (Schindeler et al., 2008, Colnot et al., 2003).  
As the evidence supported a crucial role for VEGF in bone healing, it started to be vigorously 
tested as a potential bone regeneration therapy in a myriad of preclinical models (Keramaris et 
al., 2008). Administration of VEGF was indeed found to result in increased vascularity and 
accelerated bone healing (Jacobsen et al., 2008, Street et al., 2002, Beamer et al., 2009, 
Keramaris et al., 2008), particularly when supplied in combination with BMPs (Kumar et al., 
2010, Peng et al., 2002). Notwithstanding the successes, the high hopes for VEGF-based 
therapies appear to have damped somewhat by some serious limitations. For example, 
increased levels of VEGF in the skeleton may bear a substantial risk of local side effects in 
the bone and bone marrow environment, including disturbances in hematopoiesis (Maes et al., 
2010a). Indeed, temporal VEGF over-expression in the long bones of adult mice (via an 
inducible and tissue-specific ‘gain-of-function’ approach of transgenic VEGF164) quickly 
induced combined hyper-vascularization and increased bone formation, which however 
started to obliterate the marrow cavity and cumulated in a severe pathology of osteosclerosis, 
bone marrow fibrosis and hematological anomalies after only two weeks (Maes et al., 2010a). 
Moreover, preclinical pro-angiogenic VEGF studies in cardiovascular medicine suggest risks 
for adverse vascular effects upon systemic leakage (Yla-Herttuala et al., 2007). Perhaps the 
actions of VEGF itself may be too strong to allow fine-tuned control of its use in the delicate 
bone micro-environment; other, milder and safer therapy options are therefore being 
considered for osteo-angiogenic stimulation in fractures (see (Maes et al., 2012b). For 
instance, data suggest that the VEGF homolog PlGF could be a valuable alternative (Maes et 
al., 2006), as would modulation of VEGF signaling by affecting upstream regulators such as 
HIFs and the prolyl hydroxylases that normally target HIF-1a for degradation (Shen et al., 
2009, Wan et al., 2008).  
Further in-depth analyses of the mechanisms and regulation of osteogenic cell recruitment and 
angiogenesis during fracture healing will undoubtedly help providing new therapies for 
patients with failing repair and new angles in tissue engineering applications. 
 
 
PERSPECTIVES 
 
The recruitment of osteoblasts to the site of bone formation is essential for skeletal 
development, remodeling and healing. In developing bones, osteoprogenitor cells need to 
invade the cartilage mold to form an ossification center. Similarly, osteogenic cells need to 
populate the callus that is formed following an injury and, during bone maintenance, 
osteoblasts must relocate to the sites of active bone remodeling. All these processes rely on 
controlled temporal and spatial navigation cues for the cells to find their way to the sites in 
need of new bone formation. As outlined in this review, cellular mechanisms and molecular 
pathways related to processes of in vitro chemo-attraction and in vivo recruitment of 
osteogenic progenitor cells to developing, remodeling, and healing bones are increasingly 
being documented. The further in-depth characterization of these processes will open the door 
to explore how this process can be modulated for anabolic treatment of metabolic bone 
disorders such as osteoporosis, and in fracture repair and tissue engineering. 
 
Osteoporosis is a very widespread disease that is typified by a decrease in bone mass, severe 
trabecular and cortical porosity and increased bone fragility. Osteoporosis is associated with a 
large incidence of debilitating fractures, particularly of the vertebrae and long bones, 
associated with high morbidity and mortality by virtue of complications. Already millions of 
people worldwide suffer from osteoporosis and this condition becomes increasingly prevalent 
with the ageing of the general population. The most frequent cause is the postmenopausal 
decline in estrogen levels in women; but also aging men can develop osteoporosis. Current 
estimates predict that one in three women and one in five men older than fifty will sustain an 
osteoporotic fracture, associated with pain, disability, and even death (Ström, 2011). 
The underlying basis of osteoporosis is imbalanced bone remodeling, with osteoclastic bone 
resorption exceeding osteoblastic bone formation. The most routinely used therapies against 
osteoporosis are anti-catabolic drugs such as bisphosphonates or the RANKL inhibitor 
denosumab, which inhibit the resorptive activity or the formation of osteoclasts 2,4. While 
these therapies are very successful in inhibiting excessive bone remodeling, they also imply a 
risk for slowing down (micro-) fracture repair. Moreover, they are unable to reverse the 
disease as the lost bone does not become replenished. A great need for anabolic treatments 
that increase bone formation therefore currently prevails. Few anabolic therapies exist, such 
as teriparatide, a parathyroid hormone (PTH)-based therapy, and, although still in preclinical 
studies, an inhibitor of the Wnt signaling antagonist sclerostin (Baron and Hesse, 2012, 
Rachner et al., 2011). But the clinical demand for new and better options is high; therefore, a 
great deal of interest and ongoing research worldwide is aimed at discovering safe and 
effective therapies focusing on anabolic pathways. Profound understanding of the cellular and 
molecular mechanisms mediating bone formation during bone development and remodeling, 
including the regulatory control of osteogenic cell recruitment to these sites, can help towards 
this goal. 
 
New osteo-anabolic therapies are not only of interest in fracture prevention, but also to help 
improve bone healing and (tissue-engineered) bone regeneration applications. Indeed, each 
year millions of patients suffer a bone fracture (about 6.2 million in the USA alone), 
comprising a major worldwide health problem associated with a huge burden on healthcare 
(Franceschi, 2005, Felsenberg et al., 2002). This number is only expected to rise in the future, 
as a consequence of the increasing ageing of the population and the large prevalence of low 
bone mass disorders such as osteoporosis. Bone intrinsically possesses an astounding capacity 
to regenerate upon damage, and generally, bone repair is a rapid and efficient process. 
However, in about 10% of the patients fracture healing fails, leading to delayed- or non-
unions. The causes of impaired healing often are unknown, but excessive damage to the 
periosteum (a crucial site of osteoprogenitor delivery to the healing tissue), advanced age, 
systemic disorders, or infection of the injury site are considered important risk factors. These 
problematic healing conditions pose a significant problem in orthopedics, because standard 
treatment options such as surgical intervention stabilizing the bone segments by fixation 
devices and/or reconstructive procedures using autologous bone grafts are often not feasible, 
for instance when the bone is too brittle and fixation devices and bone grafting procedures 
will be ineffective. Treatment of patients with failing fracture repair is consequently very 
challenging. The development of effective therapies for bone regeneration thus poses one of 
the most clinically and economically important long-term goals of research in the bone field 
(Franceschi, 2005). 
Current research exploring tissue-engineering-based strategies for bone regeneration therapy 
attempt to mimic events occurring during normal bone development and repair, where 
multiple factors interact in a defined temporal and spatial sequence (Weiss et al., 2012, 
Franceschi, 2005). More than 100 clinical trials on bone regeneration are presently in the 
pipeline (www.clinicaltrials.gov), implementing new findings from basic science to be 
translated into experimental, pre-clinical applicability tests (Gomez-Barrena et al., 2011). 
Tissue engineering strategies generally focus on the use of porous, biodegradable, 3-
dimensional carriers or ‘scaffolds’ providing structural support and/or osteo-inductive cues. 
These scaffolds are combined with delivery of growth factors, gene therapy protocols, and the 
use of stem cell based therapies to form viable bone grafts and achieve the best possible 
biologic outcome. Stem cell technology applications usually include human MSCs isolated 
from the periosteum or bone marrow. Yet, one of the major challenges in tissue engineering is 
to efficiently and safely expand and manipulate the progenitor cells in vitro and seed them 
onto the scaffolds before re-administration to the patient. Hence, the success of using tissue-
engineering constructs might be significantly increased if strategies would be implemented 
that stimulate the recruitment of (host-derived) osteoprogenitors to the site of the bone defect. 
Understanding the mechanisms of osteoprogenitor recruitment into developing and healing 
bones of animal models could be a vital step towards the development of new, biologically 
based therapies for the treatment of currently unmanageable skeletal injuries.  
More in vitro and in vivo experiments will be needed to expand this knowledge. Further 
studies of osteogenic cell migration and recruitment to active sites of bone formation will be 
greatly helped by sophisticated new and improved methods for cell visualization and tracing, 
such as in vivo live imaging, fluorescent and confocal microscopy methods, that can be 
combined with cell-specific and/or transiently inducible mutagenesis and reporter activation 
in transgenic mouse models. 
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FIGURE LEGENDS 
Figure 1. Mechanisms of bone development. Different skeletal elements develop through 
intramembranous or endochondral ossification as indicated on a skeletal preparation stained 
with alizarin red (bone) and alcian blue (cartilage). 
Figure 2. Stepwise representation of osteoblast (OB) differentiation from mesenchymal 
stem cells (MSC) with indication of typical stage-dependent markers. Transgenic lines 
that drive Cre expression in these cells at subsequent stages of osteoblast lineage cell 
maturation are indicated, as is the approximated developmental time of their activation. 
Figure 3. Osteoblast lineage cell recruitment into developing long bones. Schematic 
drawing of the middle portion of a developing endochondral bone. Osteoblast lineage cells 
differentiate in the perichondrium surrounding the avascular cartilage anlagen. As described 
in the text, immature osteoprogenitors (Osx/LacZ+ cells) invade the cartilage and reach the 
primary ossification center in association with blood vessels. Histological and EM images 
(reproduced from (Maes et al., 2010c)) illustrate the pericytic localization of the Osx/LacZ+ 
cells in developing bones. The osteoprogenitors, blood vessels, and osteoclasts are attracted 
into the hypertrophic cartilage by chemotactic signals such as VEGF. Cells that differentiated 
to mature osteoblasts while residing in the perichondrium (Col1/LacZ+ cells) do not move 
into the primary ossification center to generate trabecular bone, but instead form the cortical 
bone on the outside.  
Figure 4. Subsequent stages of endochondral fracture healing. In the first stage (upper left 
quarter), the injury site undergoes hematoma formation and initiates inflammatory and 
angiogenic responses. A plethora of growth factors is released in the callus. In the next days 
(post-fracture day (PFD) 4), cells in the periosteum covering the cortices adjacent to the 
injury site strongly proliferate, resulting in a thickened periosteum containing numerous Osx-
Cre:GFP+ osteoprogenitors (upper right). Mesenchymal progenitors that are recruited to the 
fracture site differentiate into chondrocytes (CH) or osteoblasts (OB). Regions of cartilage in 
the callus are gradually replaced with immature woven bone via endochondral ossification 
(EO) (lower left). This process is associated with cartilage neovascularization (around PFD 
7). Penetration of the cartilaginous callus regions by PECAM-1+ blood vessels coincides with 
recruitment of Osx-Cre:GFP+ osteoprogenitors into this area. The woven bone is further 
remodeled into in the final phase of the healing process by the actions of osteoclasts and 
osteoblasts (lower right). Fluorescent images from histological preparations are reproduced 
from (Maes et al., 2010c). 
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